NCT05571111

Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

A Randomised, Assessor-blind, Active-controlled, Parallel-group, Dose-finding Trial to Investigate the Efficacy and Safety of FE 999302 for Triggering of Final Follicular Maturation in Women Undergoing Controlled Ovarian Stimulation

• Status: Withdrawn
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Ferring Pharmaceuticals · Industry
• Sex: Female
• Age: 18 Years – 42 Years
• Healthy volunteers: Not accepted

Summary

The primary purpose of this trial is to compare three different doses of FE 999302 with 250 µg OVITRELLE and 10,000 IU NOVAREL on oocyte maturity when administered as a single dose for final development of the oocytes in women undergoing controlled ovarian stimulation.

Conditions

• Infertility

Interventions

Type	Name	Description
DRUG	FE 999302	Subcutaneous injection as a single dose. 3 different doses
DRUG	Ovitrelle	Subcutaneous injection as a single dose. 250 µg (0.5 mL)
DRUG	Novarel	Subcutaneous injection as a single dose. 10,000 IU (1 mL)

Timeline

• Start date: 2022-10-04
• Primary completion: 2024-03-25
• Completion: 2024-06-25
• First posted: 2022-10-07
• Last updated: 2023-01-09

Locations

3 sites across 1 country: Spain